AbbVie Inc. stock outperforms competitors on strong trading day
Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...
Healio6h
Connection between skin disease, heart health ushers in ‘holistic’ era of dermatology
In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...
Besremi Achieves Strong Market Growth Amid Rising Demand For Polycythemia Vera Treatment
BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...
pharmaphorum23h
AbbVie launches pump-based Parkinson’s drug in EU
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
pharmaphorum23h
Takeda spinout Phathom claims its first FDA approvals
The drug is already approved in a number of Asian markets, including Japan, and made around $900 million in sales for Takeda last year. In the PHALCON-HP trial, which involved patients without a ...